Unknown

Dataset Information

0

The association between anti-insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in children and adolescents with type 1 diabetes.


ABSTRACT: BACKGROUND:Fast-acting insulin aspart (faster aspart) is a novel formulation of insulin aspart (IAsp) ensuring ultrafast absorption and effect. AIM:To compare the pharmacokinetics between faster aspart and IAsp, based on free or total IAsp measurement, and investigate the association between anti-IAsp antibodies and faster aspart and IAsp pharmacological properties in children and adolescents with type 1 diabetes (T1D). METHODS:In a randomized, two-period crossover trial, 12 children, 16 adolescents, and 15 adults (6-11, 12-17, and 18-64?years) received 0.2 U/kg double-blindsingle-dose subcutaneous faster aspart or IAsp followed by a standardized liquid meal test. RESULTS:Across age groups, the pharmacokinetic profile was left-shifted including greater early exposure for faster aspart vs IAsp irrespective of free or total IAsp assay. Onset of appearance occurred 2.4 to 5.0 minutes (free) or 1.8 to 3.0?minutes (total) earlier for faster aspart vs IAsp (P

SUBMITTER: Biester T 

PROVIDER: S-EPMC7383777 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

The association between anti-insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in children and adolescents with type 1 diabetes.

Biester Torben T   von dem Berge Thekla T   Bendtsen Line Quist LQ   Bendtsen Mette Dahl MD   Rathor Naveen N   Danne Thomas T   Haahr Hanne H  

Pediatric diabetes 20200505 5


<h4>Background</h4>Fast-acting insulin aspart (faster aspart) is a novel formulation of insulin aspart (IAsp) ensuring ultrafast absorption and effect.<h4>Aim</h4>To compare the pharmacokinetics between faster aspart and IAsp, based on free or total IAsp measurement, and investigate the association between anti-IAsp antibodies and faster aspart and IAsp pharmacological properties in children and adolescents with type 1 diabetes (T1D).<h4>Methods</h4>In a randomized, two-period crossover trial, 1  ...[more]

Similar Datasets

| S-EPMC5054830 | biostudies-literature
| S-EPMC5385193 | biostudies-literature
| S-EPMC5394133 | biostudies-literature
| S-EPMC5222895 | biostudies-literature
| S-EPMC5425492 | biostudies-literature
| S-EPMC6451708 | biostudies-literature
| S-EPMC6588019 | biostudies-literature
| S-EPMC6973646 | biostudies-literature
| S-EPMC3132447 | biostudies-literature
| S-EPMC9541865 | biostudies-literature